Physician profile

Eric D Bullock

Hospitalist · Rockford, IL

NPI 1417067695

$431.82

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$74.55

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $130.14 2019
Janssen Pharmaceuticals, INC $108.79 2019
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $61.68 2019-2023 Lifevest
Allergan, INC. $44.65 2019
Boston Scientific Corporation $35.82 2023 Watchman Access System
Abbvie INC. $18.88 2021
Merck Sharp & Dohme LLC $18.30 2019
Kestra Medical Technology Services, INC. $13.56 2023 Assure Wcd

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eric D Bullock

$431.82

in general payments reported 2019-2025

Years
2019-2023
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/154685/eric-d-bullock

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.